Practice

Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro

October 11th 2021

By Skylar Jeremias

Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).

Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars

October 10th 2021

Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, explains how his practice has worked to inform patients and providers about biosimilars and improve their confidence in the utilization of biosimilars.

Not So Different: How One Practice Is Addressing Biosimilar Concerns Over Savings, Safety, and Efficacy

October 3rd 2021

Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, talks about the savings that biosimilars have brought to his practice and how he tackles patient and physician concerns over whether biosimilars work as well as reference products.

Sonia Oskouei, PharmD, Evaluates How Pharmacists, Interchangeability Designations Impact Biosimilar Uptake

September 29th 2021

By Skylar Jeremias

Sonia T. Oskouei, PharmD, BCMAS, DPLA, the vice president of Biosimilars at Cardinal Health, discussed the many ways that pharmacists and interchangeability designations can affect biosimilar utilization.

Alvotech Reports Positive Switching Results for AVT02 Adalimumab Candidate

September 9th 2021

By Tony Hagen

The findings support Alvotech's bid for interchangeable status for the high-concentration, citrate-free adalimumab biosimilar candidate.

Dr Gary Lyman: Formulary Placements and Physicians' Biosimilar Prescribing Patterns

August 22nd 2021

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilar placement on formularies affects physicians' willingness to prescribe these agents.

Not So Different: Dr Gary Lyman Explains How to Ensure Physician Confidence in Biosimilars

August 15th 2021

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses some of the issues holding physicians back from prescribing biosimilars and some ways to ensure provider confidence in biosimilars.

Neal Dave, PharmD, Discusses What Clinics Need to Do to Ensure Biosimilars Are Cost-efficient

August 9th 2021

Health care systems need to consistently reevaluate whether the biosimilars they utilize are the most cost-effective, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, explains.

Ophthalmology Group Opposes Payer Recommendations for Bevacizumab Biosimilars

August 4th 2021

By Tony Hagen

A supply chain shortage of Avastin (bevacizumab) is prompting policies for use of bevacizumab biosimilars instead, which the American Academy of Ophthalmology says could lead to problems.

Celltrion Dominates Republic of Korea Drug Exports, Targets Latin America

August 3rd 2021

By Tony Hagen

When it comes to exports, Celltrion Healthcare leads the way among Republic of Korea pharmaceuticals producers. The company's biosimilars are the leading exports.